# COVID-19 Vaccine Developers Gold Medal Act

This bill creates a special Congressional Gold Medal to honor everyone who contributed to developing COVID-19 vaccines. Think of it as the nation's way of saying thank you to the researchers, scientists, doctors, and other professionals—both in the United States and around the world—who worked together to create vaccines in record time.

The bill recognizes that vaccine development normally takes over a decade, but these teams accomplished it in less than a year. It acknowledges the work of university researchers, pharmaceutical companies, government agencies like the National Institutes of Health, and the volunteers who participated in vaccine trials. Congress notes that taxpayers invested about $47.6 billion in this effort through Operation Warp Speed, the government program that coordinated vaccine development and distribution.

Here's what actually happens if this bill passes: The Treasury Department will create one gold medal with appropriate designs and inscriptions. After the medal is presented, it goes to the Smithsonian Institution, where it will be displayed and available for research. The bill also allows the Treasury to make and sell bronze copies of the medal to the public, with any profits going into the U.S. Mint's fund to cover the costs of making the medals. This is a symbolic honor with minimal taxpayer cost since the bronze medal sales cover expenses.

For everyday people, this bill doesn't directly change any laws or affect your life in practical ways. It's purely ceremonial—a formal recognition of an achievement in medical science. However, it reflects Congress's view that vaccine development was a major accomplishment worth commemorating, similar to how the nation honors other significant achievements through Congressional Gold Medals.

COVID–19 Vaccine Developers Gold Medal Act

Rush, Bobby L.

COVID-19 Vaccine Developers Gold Medal Act This bill provides for the award of a Congressional Gold Medal to recognize all those whose efforts led to the development of COVID-19 vaccines that received emergency use authorizations.